{"product_id":"zynex-bcg-matrix","title":"Zynex Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eWant to skip the guesswork? Our Zynex BCG Matrix preview shows the shape of the portfolio—but the full report maps every product to Stars, Cash Cows, Dogs, or Question Marks and tells you what to do next. Buy the complete BCG Matrix for quadrant-by-quadrant analysis, data-backed recommendations, and editable Word + Excel files you can use right away. It’s the fast route to smarter allocation, clearer pitches, and decisions that actually move the needle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFlagship home electrotherapy line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFlagship home electrotherapy line sits squarely in the accelerating non‑opioid pain relief trend, with Zynex (ZYXI) core stimulators consistently favored by prescribers and patients seeking non‑invasive options.\u003c\/p\u003e\n\u003cp\u003eHigh prescription volume, strong clinician loyalty, and recognized outcomes sustain elevated share but require continuous salesforce effort, payer education, and DTC awareness to defend position.\u003c\/p\u003e\n\u003cp\u003eOngoing investment in distribution and marketing can compound adoption and scale the line into a larger revenue engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring electrodes, gels, and lead wires\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecurring electrodes, gels, and lead wires deliver clockwork reorders from Zynex’s growing installed base—consumables drive predictable, high-margin attach revenue; in 2024 Zynex reported approximately $103.5M in product revenue supporting this stream. Promotions remain light; allocation to service, logistics, and fulfillment yields higher ROI than splashy marketing. Invest in CX and fast replenishment to lock in lifetime value and scale with minimal friction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance-reimbursed pain management channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex’s playbook for scripts, documentation and approvals creates a high entry barrier for newcomers; with U.S. chronic pain affecting about 50 million adults (CDC estimate) demand supports scale. As payors in 2024 broaden coverage for non‑pharma options, volumes trend up and device market growth is ~6% CAGR. Success still needs prescriber education and clean prior‑auth workflows; nail reimbursement ops and the flywheel keeps spinning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost‑op and musculoskeletal rehab programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost‑op and musculoskeletal rehab are Stars as surgical volumes recovered to near pre‑pandemic levels by 2023, driving rising MSK device demand; outpatient PT visits exceed 200 million annually in the US, supporting recurring consumables and device use. Clinicians already trust electrotherapy to speed recovery and control pain, letting Zynex lead standardized protocols and bundle supplies to capture pathway spend. Keep clinicians engaged and scale via integrated rehab partnerships to convert referrals into recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket tag: Elective surgeries ~pre‑COVID by 2023\u003c\/li\u003e\n\u003cli\u003eVolume tag: US outpatient PT visits \u0026gt;200M\/year\u003c\/li\u003e\n\u003cli\u003eStrategy tag: Protocols + bundled supplies = pathway ownership\u003c\/li\u003e\n\u003cli\u003eGrowth tag: Scale through clinician ties \u0026amp; rehab partnerships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. direct sales footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of 2024 Zynex's U.S. direct-sales footprint is broad and trained for a referral-driven model, creating a moat that's hard to replicate quickly; market growth plus disciplined field execution support durable share gains. The channel still needs enablement—better data tools, compiled case studies, and faster onboarding—to scale efficiently. Adding reps in high‑yield regions shows rapid payback given current referral economics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: referral-tuned, hard to copy\u003c\/li\u003e\n\u003cli\u003eDurability: market growth + field execution\u003c\/li\u003e\n\u003cli\u003eNeeds: data tools, case studies, faster onboarding\u003c\/li\u003e\n\u003cli\u003eOpportunity: add reps in high-yield regions for quick ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome electrotherapy \u0026amp; MSK rehab: \u003cstrong\u003e$103.5M\u003c\/strong\u003e revenue, \u003cstrong\u003e~6%\u003c\/strong\u003e CAGR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZynex’s home electrotherapy and MSK rehab lines are Stars—strong share in a ~6% CAGR device market with tailwinds from ~50M US adults with chronic pain and \u0026gt;200M annual outpatient PT visits. 2024 product revenue ~103.5M supports recurring consumables and high-margin attach rates. Continued field investment, payer wins, and onboarding tools will scale share and lifetime value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTag\u003c\/th\u003e\n\u003cth\u003eMetric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct rev\u003c\/td\u003e\n\u003ctd\u003e$103.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic pain US\u003c\/td\u003e\n\u003ctd\u003e~50M adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePT visits\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket CAGR\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG analysis of Zynex products with insights per quadrant and clear invest\/hold\/divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Zynex BCG Matrix that clarifies portfolio pain points for fast C-suite decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy stim devices still in circulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy stim devices still prescribed and serviced in 2024 require minimal R\u0026amp;D investment and deliver predictable cash flow via low-maintenance service and steady consumable sales. They generate recurring margins with little promotional spend beyond compliance and support. Strategy: maintain the installed base and optimize service economics—milk, don’t remodel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumable auto‑replenishment program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsumable auto-replenishment acts as a cash cow for Zynex: subscription-like reorders are efficient, sticky, and margin-rich, with subscription businesses showing ~17% YoY growth in 2024 per Zuora and median retention near 85%. Operations tweaks (pick\/pack, routing) directly drop to the bottom line, often cutting fulfillment costs materially. Marketing is modest; retention and reminders do the heavy lifting. Invest in systems to keep churn low and invoices paid.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical education libraries and CE partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical education libraries and CE partnerships are evergreen cash cows: built once, they keep referrals flowing with minimal incremental cost and reinforce Zynex as the safe, reimbursable choice. Maintenance is cheap, payoff steady—keep the lights on and update annually to preserve accreditation and clinician trust. Annual refreshes in 2024 sustain credibility and referral momentum without large CAPEX. Bank the trust through consistent, accredited content.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor relationships in mature regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDistributor relationships in mature regions deliver predictable cash flows from stable territories with known payers and steady script counts; contracts and routine servicing keep churn low and operational costs controlled. Upside is modest, typically mid-single-digit organic growth, while cash generation funds investment elsewhere. Hold the line, optimize contract terms, and avoid distraction from strategic priorities.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable territories\u003c\/li\u003e\n\u003cli\u003eKnown payers\u003c\/li\u003e\n\u003cli\u003eRoutine servicing\u003c\/li\u003e\n\u003cli\u003eModest upside\u003c\/li\u003e\n\u003cli\u003eReliable cash\u003c\/li\u003e\n\u003cli\u003eOptimize terms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement operations and billing engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReimbursement operations and billing engine drive cash efficiency: process expertise cuts denials to below the 5–12% industry range (2024), producing faster approvals and cleaner cash flow. Dialed-in, scalable workflows mean incremental investments can improve DSO by ~10–20% and lift yield 3–5%. Keep tuning the machine while competitors wrestle with paperwork.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: fast approvals, fewer denials\u003c\/li\u003e\n\u003cli\u003eScale: workflows easily expanded\u003c\/li\u003e\n\u003cli\u003eImpact: DSO down ~10–20% (2024)\u003c\/li\u003e\n\u003cli\u003eYield: incremental gains ~3–5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumable subscriptions fuel steady margins - \u003cstrong\u003e~17%\u003c\/strong\u003e YoY, \u003cstrong\u003e85%\u003c\/strong\u003e retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy stimulators, consumable subscriptions, clinician education and mature distributor territories form Zynex cash cows, delivering steady margins with minimal R\u0026amp;D or marketing; consumables show ~17% YoY growth (Zuora 2024) and ~85% retention. Optimized reimbursement cuts denials toward the 5–12% industry range, improving DSO ~10–20% and yield ~3–5%, funding growth elsewhere.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumable YoY\u003c\/td\u003e\n\u003ctd\u003e~17%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDenials (industry)\u003c\/td\u003e\n\u003ctd\u003e5–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDSO improvement\u003c\/td\u003e\n\u003ctd\u003e~10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield lift\u003c\/td\u003e\n\u003ctd\u003e~3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor growth\u003c\/td\u003e\n\u003ctd\u003emid-single-digit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eZynex BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Zynex BCG Matrix you're previewing on this page is the exact, final file you'll receive after purchase. No watermarks, no placeholders—just a fully formatted, analysis-ready report built for strategic decisions. Once bought, the same document is instantly downloadable and editable for presentations or planning. Simple, professional, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163385573753,"sku":"zynex-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/zynex-bcg-matrix.png?v=1762718824","url":"https:\/\/portersfiveforce.com\/products\/zynex-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}